News

“Our year-to-date revenues of CAD17.6 million are slightly below last year due to reduced volume in our Bioanalytical division. We have had an unprecedented number of cancellations and

Emergent BioSolutions has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio foundation and the land on which the facility stands from the city of

Esperion Therapeutics has initiated a Phase I clinical study for ETC-1002, the company’s novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

Ipsen has reported that the French Regulatory Authorities (AFSSAPS) have granted the marketing authorisation to the 6-month sustained-release formulation of Decapeptyl (triptorelin embonate1 22.5 mg) for the treatment

Axelar has reported that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, is expected to be presented at the AACR-NCI-EORTC International

Talecris Biotherapeutics and NC Gov Bev Perdue have reported that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.

UnitedHealth, Prescription Solutions and the National Council on Patient Information and Education (NCPIE) have released a new survey, which shows that 54% of Americans say they do not

Sanofi-aventis is due to announce the results of cross-sectional study of ‘SITE’ (Screening India’s Twin Epidemic). The objective of the study was to quantify and instill awareness amongst

“HairDX is a very valuable tool to determine early stages of Androgenetic Alopecia. Noninvasive treatment possibilities are greatly enhanced by early action on Androgenetic Alopecia,” says Dr. Carlos